Lafferty K J, Woolnough J
Immunol Rev. 1977;35:231-62. doi: 10.1111/j.1600-065x.1977.tb00241.x.
Previous explanations for the allograft reaction have been based on the concept that antigen causes immunocyte activation, following engagement of the immunocyte's specific receptor. This notion lead to the concept of immune surveillance, the idea that the evolutionary pressure responsible for the development of the vertebrate immune system involved in allograft rejection was a need to recognize and destroy tumor cells that carried novel antigens. Allografts were rejected because they were, in effect, mistaken for tumor cells. At the practical level, these ideas suggested that a solution to the allograft problem required treatment of the recipient in a way that would reduce or eliminate the recipient's immune response to the grafted tissue. We have rejected these ideas on the grounds that the basic premise, the notion that antigen alone drives T cell differentiation, is invalid. To explain the origin of the allograft response, we have developed a theory of allogeneic reactivity based on the concept that a stimulator cell is required for the activation of blood cells involved in both nonspecific inflammatory reactions and specific cellular immunity. This theory provides a conceptual link between invertebrate and vertebrate alloreactivity and explains why the MHC and factors controlling the expression of T cell activity map in the same region of the genome. According to this theory, it is blood cells carried within the transplanted tissue and not transplantation antigen on the surface of graft parenchymal cells, that constitute the major barrier to allotransplantation. Experimentally we have presented evidence for a two-signal mechanism for T cell activation. Both antigen and an inductive stimulus are required for T cell activation, and neither factor alone induces detectable T cell activation. Organ culture of thyroid tissue for 4 weeks renders it non-immunogenic without altering its antigenic composition. Furthermore, cyclophosphamide pretreatment of the thyroid donor, a procedure that does not destroy the vascular bed of the donor tissue, also reduces its immunogenicity. These findings are of both theoretical and practical importance. They show that transplantation antigen carried on the parenchymal cells of a transplant do not constitute the major barrier to allotransplantation and, at least in the case of thyroid and parathyroid transplantation, indefinite allograft survival can be achieved by treatments directed at the transplanted tissue and not the recipient.
以往对同种异体移植反应的解释基于这样一种概念,即抗原在与免疫细胞的特异性受体结合后会导致免疫细胞激活。这一概念引出了免疫监视的概念,即负责同种异体移植排斥反应的脊椎动物免疫系统进化压力源于识别和摧毁携带新抗原的肿瘤细胞的需要。同种异体移植被排斥是因为它们实际上被误认为是肿瘤细胞。在实际层面上,这些观点表明,解决同种异体移植问题的方法需要以减少或消除受体对移植组织的免疫反应的方式来治疗受体。我们摒弃了这些观点,理由是其基本前提,即仅抗原驱动T细胞分化的概念是无效的。为了解释同种异体移植反应的起源,我们基于这样一种概念发展了一种同种异体反应性理论,即激活参与非特异性炎症反应和特异性细胞免疫的血细胞需要一个刺激细胞。该理论在无脊椎动物和脊椎动物的同种异体反应性之间建立了概念联系,并解释了为什么主要组织相容性复合体(MHC)和控制T细胞活性表达的因子在基因组的同一区域定位。根据这一理论,构成同种异体移植主要障碍的是移植组织内携带的血细胞,而不是移植实质细胞表面的移植抗原。在实验中,我们提供了T细胞激活的双信号机制的证据。T细胞激活需要抗原和诱导刺激,单独任何一个因素都不会诱导可检测到的T细胞激活。甲状腺组织进行4周的器官培养会使其失去免疫原性,而不改变其抗原组成。此外,对甲状腺供体进行环磷酰胺预处理(该程序不会破坏供体组织的血管床)也会降低其免疫原性。这些发现具有理论和实际重要性。它们表明,移植实质细胞上携带的移植抗原并不构成同种异体移植的主要障碍,并且至少在甲状腺和甲状旁腺移植的情况下,通过针对移植组织而非受体的治疗可以实现同种异体移植长期存活。